Pomalidomide Market

The Pomalidomide market is projected to grow at a CAGR of 5.8% from 2025 to 2035, driven by rising cases of multiple myeloma and a growing emphasis on targeted cancer therapies. Pomalidomide, an immunomodulatory agent and derivative of thalidomide, has become an essential treatment for patients with relapsed or refractory multiple myeloma. Expanding approvals for additional indications, such as Kaposi sarcoma, have broadened its therapeutic scope. Moreover, increasing awareness about hematologic malignancies and improved healthcare access in emerging economies are contributing to a wider patient base. The patent expiration of branded formulations is expected to encourage generic competition, enhancing affordability and market penetration.

Geographically, North America dominates the Pomalidomide market, driven by a high prevalence of multiple myeloma, advanced healthcare infrastructure, and rapid uptake of new oncology treatments. Europe holds a substantial share, especially in countries like Germany, France, and the United Kingdom, supported by reimbursement policies for cancer treatments. Asia-Pacific is the fastest-growing region, fueled by the increasing incidence of blood cancers, growing health expenditures, and the rising availability of generic pomalidomide options in China, India, and Japan. Latin America and the Middle East & Africa are experiencing moderate growth, mainly due to improvements in oncology care access and expanding pharmaceutical distribution networks.

The market report is evolving by sustainable growth, powered by expanding indications, rising cancer prevalence, and growing generic competition. Companies that invest in expanding geographic reach, securing regulatory approvals, and optimizing patient support programs are likely to succeed in capturing greater market share. The shift toward combination therapies and biosimilars will further define the competitive landscape through 2035.